![](https://ml.globenewswire.com/media/d9b4b478-f8bd-4014-91ed-429caab67931/small/atyr-logo-png.png)
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second quarter 2024 with $81.4 million in cash, cash equivalents, …